



Expanded Access Policy

Version 1.0; 20-FEB-2026

Aktis Oncology is committed to improving outcomes for cancer patients by pioneering a new class of targeted radiopharmaceuticals addressing prevalent tumor types that historically have been beyond the reach of radiopharmaceuticals.

Investigational drugs that have not been approved by a regulatory authority (e.g. the Food and Drug Administration in the United States), may or may not be safe and effective as a treatment option. Clinical trials are designed to evaluate the safety and efficacy of investigational drugs. Expanded Access refers to the use of an investigational drug when the primary purpose is to diagnose, monitor, or treat a patient's disease or condition rather than to obtain the kind of information about the drug that is generally derived from clinical trials.

Given the current early stage of clinical development, Aktis Oncology does not offer its investigational drug products as part of an Expanded Access Program. We encourage patients to discuss their eligibility for a clinical trial with their treating physician(s). Information about our ongoing clinical trials including eligibility criteria and locations, can be found at the following link: clinicaltrials.gov.

We recognize patient interest in Expanded Access Programs; therefore we will continue to evaluate our policy based on a number of factors, including emerging data from ongoing and future clinical trials. Please contact us for any questions you may have regarding our Expanded Access Policy.